BioAegis Therapeutics

About:

BioAegis is developing therapeutics for infectious, inflammatory and degenerative diseases based on the platform of plasma gelsolin.

Website: http://www.bioaegistherapeutics.com

Twitter/X: bioaegis

Description:

BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.

Total Funding Amount:

$42.3M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Morristown, New Jersey, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)bioaegistherapeutics.com

Founders:

Steven Cordovano, Susan Levinson, Thomas P. Stossel

Number of Employees:

1-10

Last Funding Date:

2022-03-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai